PROCEPT BioRobotics Corporation (PRCT)
| Market Cap | 2.00B |
| Revenue (ttm) | 299.91M |
| Net Income (ttm) | -84.58M |
| Shares Out | 55.88M |
| EPS (ttm) | -1.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,303,664 |
| Open | 35.53 |
| Previous Close | 35.43 |
| Day's Range | 35.50 - 38.11 |
| 52-Week Range | 27.80 - 98.38 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 56.57 (+57.75%) |
| Earnings Date | Nov 4, 2025 |
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign p... [Read more]
Financial Performance
In 2024, PROCEPT BioRobotics's revenue was $224.50 million, an increase of 64.84% compared to the previous year's $136.19 million. Losses were -$91.41 million, -13.68% less than in 2023.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for PRCT stock is "Strong Buy." The 12-month stock price target is $56.57, which is an increase of 57.75% from the latest price.
News
PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025
SAN JOSE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solut...
Artisan Global Discovery Fund: Q3 Delivers Strong Results Amid Trimming And Exits
The portfolio generated a modestly positive absolute return in Q3, but it trailed the MSCI All Country World Small Mid Index. The Q3 underperformance was driven by stock selection in the IT, financial...
PROCEPT BioRobotics Corporation (PRCT) Q3 2025 Earnings Call Transcript
PROCEPT BioRobotics Corporation ( PRCT) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Matthew Bacso - Vice President of Investor Relations Larry Wood - President, CEO & Dire...
PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance
SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfo...
2 Robotics Stocks Riding the Sensor and Medical Boom
Robotics companies building enabling systems like sensors and LiDAR attracted $1.6 billion in 2025, as every robot needs vision capabilities. Medical robotics shows the clearest path from startup to p...
Is Procept BioRobotics Stock a Buy After Investment Company Chicago Capital Scoops Up Nearly 1 Million Shares?
Chicago Capital added 999,873 shares of Procept BioRobotics with an estimated purchase value of $45.65 million based on the average price for the quarter. The transaction represents a trade size equal...
PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025
SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transfo...
Procept BioRobotics: A Strong Challenger Positioned To Be A Future Leader
PROCEPT BioRobotics stands out in BPH therapy with its unique Aquablation technology and razor-and-blade business model, driving strong, recurring growth. PRCT's robust R&D investment, expanding indic...
Procept BioRobotics: Increasing Average Selling Price, Initiate At Buy
Procept BioRobotics Corporation is in the early stages of penetrating a massive $20B BPH surgery market with its innovative, recurring-revenue robotic systems. The company's strong revenue and install...
PROCEPT BioRobotics Corporation (PRCT) Q2 2025 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Kevin Waters - Executive VP & CFO Larry L. Wood - Independent Director Ma...
Procept (PRCT) Q2 Revenue Jumps 48%
Procept BioRobotics (PRCT -5.28%), a medical technology company specializing in robotic surgical systems for benign prostatic hyperplasia (BPH) treatment, posted second-quarter 2025 results on August ...
PROCEPT BioRobotics (PRCT) Earnings Transcript
Image source: The Motley Fool.
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfo...
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (“the Company”), a surgical robotics company focused on advancing patient care by developing transformative solut...
Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy
SAN JOSE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformat...
PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025
SAN JOSE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transfo...
Aquablation® Therapy's Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformat...
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solu...
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, ...
PROCEPT BioRobotics Corporation (PRCT) Q1 2025 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations & Business Operations Rez...
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transf...
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment global...
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomiz...
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada
SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfo...